Apimeds Pharmaceuticals US (APUS) EPS (Basic) (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) posted EPS (Basic) of -$0.67 for Q4 2025, down 369.11% on a QoQ basis from -$0.14 in Q3 2025, and down 1277.97% year-over-year from $0.06 in Q4 2024.

Apimeds Pharmaceuticals US (APUS) EPS (Basic) (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US's EPS (Basic) history runs 2 years deep, the most recent figure standing at -$0.67 for Q4 2025.

  • Quarterly EPS (Basic) fell 1277.97% year-over-year to -$0.67 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.12 (down 503.57% YoY) and the FY2025 annual result came in at -$1.33, down 334.93% from the prior year.
  • EPS (Basic) was -$0.67 for Q4 2025 at Apimeds Pharmaceuticals US, down from -$0.14 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.04 in Q1 2024 and bottomed at -$0.67 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Basic) (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 0.32
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 1.42
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -1.49
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 6.32
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 0.15
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 1.97
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 0.11
10 Apimeds Pharmaceuticals US 61.48 Mn 61.48 Mn - -0.67

Historic Data

Download Data
DateValue
Dec 31, 2025 -0.67
Sep 30, 2025 -0.14
Jun 30, 2025 -0.26
Mar 31, 2025 -0.05
Dec 31, 2024 -0.05
Sep 30, 2024 -0.04
Jun 30, 2024 -0.06
Mar 31, 2024 -0.04